This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB05414/identifier/bindingdb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05414/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05414/identifier/drugbank/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB05414/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB05414/identifier/wikipedia/

Statements

Subject Item
n2:DB05414
rdf:type
n3:Drug
n3:description
ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment for metastatic breast cancer.
n3:group
investigational
n3:indication
Investigated for use/treatment in breast cancer.
owl:sameAs
n8:DB05414
dcterms:title
ERA-923
adms:identifier
n6:Selective_estrogen_receptor_modulator n9:DB05414 n10:6433099 n12:50099587 n13:4938287
n3:mechanismOfAction
ERA-923 inhibits estrogen-stimulated growth associated with cytostasis. It has been shown to have a potent, selective oestrogen modulating effect, with few uterine side-effects.
n3:IUPAC-Name
n4:271B4308-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B430E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B430D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B430A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B430B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B430C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4306-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4304-363D-11E5-9242-09173F13E4C5 n4:271B4307-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4305-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4314-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4315-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B430F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4310-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4312-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4311-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4313-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B431A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B431C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B431D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4319-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4318-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B431B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4309-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4316-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4317-363D-11E5-9242-09173F13E4C5